Archive for the ‘Conference Coverage with Social Media’ Category

LIVE Day 2 – 2017 MassBio Annual Meeting  March 31, 2017 8:00 AM, Royal Sonesta Boston

Real Time Coverage: Aviva Lev-Ari, PhD, RN

 #MassBioAM17 #PATIENTDRIVEN @pharma_BI @AVIVA1950

Day 2


8:00 am 8:30 am

Pain & Addiction

Trends in Science
8:30 am 9:30 am
MODERATOR: Vipula Tailor, Medical Immunology
  1. transdermal transmission
  2. same platform for DM
  3. Gender threshold
  4. Transition from current drugs to new drugs
  5. lower dose for same efficacy
Michael Heffernan, Founder, President & CEO, Collegium Pharmaceutical Inc.
  1. Drug Extenza – ER, safer opioids
  2. 2-4 million needs opioids to function in the US
  3. only 4% of opioids are abused in the US
  4. Access – Insurance, MedicCare, MedicAid – do not pay for it, doctors need preauthorization
  5. opioids brings euphoria, mood change
  6. efficacy – 24 hours, 48 hours, 72 hours
  7. evolution of thinking
  8. metabolic aspects, half life
  9. Best Practice in patient selection for clinical trials – who to select and HOW to screen
  10. Placibo vs Drug, causing constipation, Impact Group, the data needs be shared
  11. Opioid abuse in the US, evolution in patient selection if they are not a candidate for opioids
  12. Comprehensive treatment, pain management is only one component PT, and counseling education, multimodal treatment
  13. MassHealth, only if you fail opioids one will get Fentanyl
  14. Decrease Opioids prescribed in MA,
Ajay Yekkirala, CSO and co-Founder, SUBSTITUTE for Michio Painter, Co-Founder & CEO, Blue Therapeutics
  1. molecule smaller than morphine
  2. 40% are in chronic pain every day,
  3. target in nervous system, peripheral pain,
  4. sensitisation in the CNS will bypass opioids
  5. Placibo effect
  6. Class II hard to prescribe
  7. Reimbursement aspects – IV administration
  8. 20% of Patients on opioid for 5 days will stay on the drug for 2-3 years
  9. Gender differences – more Female in Chronic Pain than Males
  10. Types of Pain: Fibromyalgia vs Post OPS pain
  11. sharing information of clinical trial on Drug for Pain will be very helpful on Research
John J. Renger, PhD, Head of Clinical Research, Purdue Pharma, L.P.,
  1. sleep and pain
  2. change from systemic to local administration for efficacy
  3. Pain pathways of Pain – four different pathwave each specific for drug development
  4. Acute pain becomes chronic pain
  5. Formulation as target
  6. End point definition – for clinical trial design, time line and expense a challenge for small bio companies
  7. behavior studies, genetics studies, who respond to what pathway the best
  8. Genetic profile for efficacy, side effect of responders
  9. Drug of choice for a type of pain
  10. electrical stimulation
  11. genetic studies PRIOR to participation in Clinical Trial
Frank Reynolds, CEO, PixarBio
  1. local injection opioids
  2. pre-clinical data
  3. local toxicity
  4. morphine strength
  5. 14 day treatment max – analgesia
  6. Animal model for Chronic pain is a challenge
  7. Interrupt in sleep effect on mood, pain signal
  8. Drug used in Epilepsy and in Parkinson
  9. Opioids causes respiratory involvement a problem in Children and Elderly

Next Generation Diagnostics

8:30 am 9:30 am


Better Business
9:30 am 10:30 am


Trends in Science
9:30 am 10:30 am

Kiran Reddy, President & CEO, Praxis Precision Medicines

  1. AlzheimerDisease and Parkinson
  2. Now imaging technology used in Parkinson and in AD
  3. Neuro inflammation in Neurodegenerative diseases: Over or Under activity
  4. other therapeutics areas
  5. No biotech in Neuro degeneration from VC point of view – AD and Parkinson, only big Pharma
  6. CNS was small molecule now moving to gene therapy
  7. Deep brain stimulation for Parkinson
  8. Imaging and Diagnostics for CNS disease
  9. CNS and Psychiatry, ADHD – innovations stopped – How to reinvigorate Psych drug development
Stephen Curtis, Director, BD, Emerging Technologies & Innovation, Eli Lilly & Co.
  1. Eli Lilly is committed to three targets under development: Tau, Neuro inflammation
  2. Patient selection for Clinical Trials
  3. Pain is emerging in high interest, one molecule was licensed – now AD and ALS – psychosis
  4. improve patient quality of life
  5. Life Sciences Funds in the UK, Eli Lilly invest there, other Big Pharma are also investing in this Fund
  6. Which pathways and cognition scoring and digital to identify early cognitive decline
  7. Diagnostics Business Model in Venture Financing – a difficult field
Zaven Kaprielian, Neuroscience Research, Amgen
  1. Amgen since 1999 partnered with Novartis for Clinical Trial on AD
  2. Decogenics, app pathway, link between Nate immune and AD
  3. activation of microglia to accelerate clearance
  4. genetic targets in ALS
  5. pathways convergence
  6. Autism, genetic players
  7. longevity and CNS disease
  8. Biomarkers Consortium effort on its way
  10. Human genetics sequencing families
Penny Hallett, Director, Neuro regeneration Research Institute, McLean Hospital & Asst Prof. HMS
  1. Parkinson – neuron loss has no recovery of the loss
  2. Biomarkers
  3. Parkinson, antibodies, lysosomal targets physiology better understood
  4. Inflammation and Microbiome changes linked to inflammation and inflammatory response
  5. Autonomic dysfunction
  6. chronic systemic infection
  7. Phenotype mutation in Parkinson

Coffee Break

10:30 am 10:45 am

Patient Story

10:45 am 10:50 am


11:00 am 12:00 pm
Frank David, Managing Director, Pharmagellan
  1. Why do we care about Convergence
  2. Digital, Diagnostics, Devices


Anne Deconinck, Exec Director, Koch Institute, MIT
  1. Biological discovery: Engineers and Life Scientist to work on Cancer
  2. Collaboration, synergies, shared mission
  3. diversity, different mind sets,
  4. convergence: Early detection, nanovision for early detection
  5. devices
  6. genomics
  7. following individual cells in the presence of drugs
  8. T-cells and vaccines as therapeutics
  9. 50 companies were span off from MIT in last five years, some in Clinical Trials
  10. Partnerships with Pharma with funds
  11. One Faculty with a Team for each Labs
  12. Helping Oncologists making decisions on leukemia using a platform for drug match to patients in Cancer
  13. ML ids the future for Wellness data to predict disease and improve diagnosis
  14. New Vaccines,
Ryan Egeland, Sr. Director, BD & Licensing, Medtronic, Surgical Group
  1. Drug eluting stents
  2. balloons
  3. device and drug
  4. Pacemaker implantable – Digital IT
  5. $12 Bil Revenues of Medtronic
  6. Big Pharma $450Billion, devices is a small portion
  7. Inefficiencies in HealthCare including Dealth by error of treatment or surgical
  8. 1989, Human Genome Project, George Church foresaw Sequencing the Human Genome for less than $1000
  9. CHF – expensive disease, time sensitive
  10. MI – disease stage – idea from Lab to development of device
  11. Medtronics is Patient centered
  12. Quality and Health Measure
  13. Profit and Loss statement: Presence in Device in Pharma – Staff, allocation of staff, IOM – utilize resources in Healthcare
  14. Peak of Healthcare IT, the trough will come, The Genomics Renaissance will come soon and will touch Devices in 5 years
John Halamka, CIO, BIDMC, solving IT problems
  1. $2Billion cost of Hospitalization,
  2. Patient consent for treatment
  3. Living Health Care Systems, objective and subjective data from Patients, Phenotype and Genotype
  4. Business Rules applied to EMR, glucometer data,
  5. Biomarkers used based on Probabilistic model of a disease in a Patient
  6. Patient interface with a New Application at BIDMC: Who is on the Team for this day, what tests will be done what id the Plan of Care for the day
  7. Care patient of Geriatric Patient is a Growing Business
  8. Amazon is hosting in the cloud the Data from BIDMC — the Renaissance in IT is NOW
Rachel Sha, Head, Central Transactions & Digital BD, BD & Licensing, Sanofi
  1. Drugs: Cheaper, faster – HOW
  2. Digital development in DM – technology known the variance is life style and exercise
  3. short term and long term – chasing butterflies
  4. What to do with DM Data??
  5. Appetite for Innovations at Sanofi: drug investment
  6. Midway: speed of uploading data is enabling to innovate

Patient Story

12:00 pm 12:05 pm

Buffet Lunch

12:05 pm 12:45 pm

Patient Story

12:45 pm 12:50 pm

Closing Keynote: What Corporate Executives Can Learn from Donald Trump’s Presidential Victory

1:00 pm 1:30 pm

Dessert Buffet & Networking Reception

1:30 pm 2:00 pm

Read Full Post »

LIVE Day 1 – 2017 MassBio Annual Meeting  March 30, 2017 8:00 AM, Royal Sonesta Boston

Real Time Coverage: Aviva Lev-Ari, PhD, RN

#MassBioAM17 #PatientDriven @pharma_BI @AVIVA1950

Day 1

Breakfast and Registration

8:00 am 9:00 am

Welcome Remarks & MassBio Board Elections

9:00 am 9:30 am
Robert Coughlin, CEO, MassBio
  • 63,000 emp
  • 1600 drugs in the pipeline
  • 3 million cures in the near future
  • Life Sciences Challenges
  • Negative impact on Biotech Industry: Policies from the New Administration: Repeal & Replace ACA, Travel Ban, Health coverage, cost and access
  • proposed cuts to NIH, devestation to Institutions in MA
  • Drug costs and Price Transparencies
  • MassBio — opposed these policies from Washington
  • MassBio will continue to lead like with ACA
  • MassBio will continue to embrace Value-based Contracting and will continue to suppost generics which will lower drug costs
  • MA is HQS of Biotech, partnered with NEHA, biopharma and BlueCross BlueShield
  • ENsuring Patient access and drug affordability
  • MA Health Insurance (BlueCross BlueShield) partners with Biotech and Pharma to identify strategy to reduce cost and Monitor Value-based Contracting
  • Vibrant Healthcare Sector and Innovative Biotech
  • Saving Lives is the goal
  • List of Sponsors is Long: Catalent, Corealis, fisherscientific, Amgen, Biogen, Nutter, SHire, Radius, Snow, Uniqure, MA Life Sciences Center
  • Charlie Brown in the afternoon, committed to the goals of MassBio
Abbie Celniker, Chair, MassBio Board of Directors
  • MassBio works as a collective advocacy agency of multiple stakeholders
  • Work together as Partners
  • Engagement, Involvement
  • Community experiencing growth and maturation, average income $140,000 commercial Lab work spaces
  • Diversity workforce, immigrants, spectrum of cultures, gender and training
  • Survey: Female Mangers represent commitment, credentialing, 50% of companies surveyed SVP less hopeful than above and below
  • Culture and Values alignment for employ retention, primarily Women

Opening Keynote

9:30 am 10:15 am
Dan Schorr, Founder, Chief Icecream Officer, VICE CREAM

Coffee Break

10:15 am 10:30 am

Challenges the Future Generation of the Industry Faces

Better Business
10:30 am 11:30 am
Johannes Fruehauf, Co-founder, LabCentral
  1. Postdoc at Harvard, transition from Academic environment to commercial, not awareness of Biotech industry, in Germany went through Medical School and was aware of Big 200 years old Pharma companies
  2. CROs in Boston, Automated Labs, workflow outsourced if alck of funding
  • Will Adams, CSO, President, Founder, Riparian Pharmaceuticals – CVD drug development
  1. human genetics, differential biology, therapeutics for CVD
  2. Lab at HMS research on Vasculture, one important pathway
  3. NIH – $500,000
  4. Using CROs
  • Chris Colbert, Director of Programming, Harvard Innovation Lab – seminars open to the Public
  1. Harvard Entrepreneur activity for students and Alunmi, started EdTech in 2014, defining problems and solutions
  2. Education vs outcomes – capacity to start a business
  3. complementary to Education, resources to become entrepreneur
  4. individuals are driving the process
  5. AI
  • Tim Wang, Co-founder, KSQ Therapeutics
  1. at MIT, now with VC at KSQ, 30-40 emp, hires are computentional biology, cancer biology from pulls of Boston-based Postdocs,
  2. involvement in wriitng a business plan and funding
  3. being active and interdisciplinary


Trends in Science
10:30 am 11:30 am

Evolution of Analytics in Life Sciences: The Past, the Present and Future of Analytics

10:30 am 11:30 am

The MassBio Annual Awards Luncheon

11:45 am 1:15 pm
11:55 – 12:00 Patient Story
12:00 – 12:30PM 2016 Joshua Boger Innovative School of the Year Award – Presented to Hingham High School
12:30 – 1PM 2016 Henri A. Termeer Innovation Leadership Award
Presented to David Meeker, Executive VP and Head of Sanofi Genzyme
  • Sources of inspirations Henri A. Termeer the founder of Genzyme
  • Consumer of HealthCare for 62 years is critical: Trust and Access for vulnerable patient when they are ill
  • Return on Investment in Drugs, incentives to develop vs generics, BioSimilars, Price will drop
  • Societal contract: Recognizing the value and the Pharma Industry needs to increase self regulating
  • If Gov’t will regulate PRICE of drug, innovations will decrease
  • Thank you for the award
1:00 – 1:15 2017 MassBio Leading Impact Award introduced by EDAC Chair Mark Bamforth – Lab Space
Presented to Pfizer, Accepted by Morrie Birnbaum, SVP & CSO, Internal Medicine
  • 2100 emp in MA
  • single building in Kendall Square
  • Andover facility
  • three R&D units: Drug Discovery

Pfizer, Accepted by Morrie Birnbaum, SVP & CSO, Internal Medicine

  • 2014 – Kendall Square site: Becoming Premier Pfizer’s Research Center, close to Science, Scientists and Patients
  • Recognition that working with Foundations and Academic centers Not able to do it alone
  • Close relations with MassBio
  • Thanks to MassBio

Remarks from Governor Charlie Baker

1:15 pm 1:30 pm
  • Patient Driven – Governor Charlie Baker
  • MA #1 in STEM occupations
  • Knowledge ecosystem at Kendall Square
  • Smart Fibers HQS: MIT and MA players joint investment
  • Robotics Competition in MA
  • BioPharmaceutical Competision: WPI, MIT State of MA, ULowell – joint investment
  • IBM Watson in MA, MA Life Sciences Center
  • Discovery and inquiry – MA is a place people look from where solutions will come
  • Four big element: Grant from MA Life Sciences Center gave Lab equipment to Brimfield High School
  • Collaborate with Academia for apprenticeship
  • Partnership: Draper Lab and Mass Eye and Ear: develop drug eluting device with drug for Macular Degeneration to replace the needle in an injection into the eye
  • Invest in workforce – human training skills for the technology sector
  • Public Transportation Investment: Replace from mechanical to digital in 2022 all switches of the T system – Double capacity on Red Line, manufactured in Springfield, MA
  • Affordable Housing Units: MA State Housing Dept largest owner of Housing in MA in area near Public Transportation
  • MassBio – Part of the MA economy with less problems that other industries

Cancer Moonshot and other Cancer related issues

1:30 pm 2:30 pm
MODERATOR: John Hallinan, CBO, MassBio
  • Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute
  1. Was part of Cancer Moonshot – 10 key directions
  2. Fund $1.8 Billion, fund needs be approved each year
  3. Funds for 12 implimentation Teams – Applications for 10 key directions: How a Tumor evolve and resist treatment
  4. Create an initiative of Data Sharing acquired from Patients
  5. understanding mutation unique
  6. cancer immunotherapy: fight tumor, stimulate immune system CHeck-Point blockers – only 20% of patients are responsive
  7. Big data to identify new drug targets so more patients will respond
  8. Tsunami in BioMedical Research regarding NIH to face $1.2 Billion cut (equal indirect cost)  – Patients are best advocates –
  9. MA figured out how to do collaboration among stackholders
  10. Several Cancers will become Chronic diseases not quite Cure in 5-10 years
  11. Prevention and early detection: Vaccination, HPV (only 14% girls get vaccine for Cervical, anal and throat) in Japan 0% of HPV.
  12. environment that surrounding the tumor, immune cells suppressing the immune system
  • Mathew Meyerson, Prof. of Pathology, Dana-Farber Cancer Institute, Broad Institute
  1. 3-D cancer genomics sequencing for every cell, new therapies interaction of Cancer and the environment, computing and Internet use for Patient direct involvement in Research – enrollment
  2. Child Cancers
  3. Prevention: Vaccination, HPV, HEP B
  4. HIV a cocktail of drugs, kill a cancer from many angles
  5. access to clinical trial: Connect Clinical Trials information with Doctors
  6. Electronic cigarets and Lung cancer – connection needs to be researched
  • Chandra Ramanathan, Head East Coast Innovation Center, Bayer US
  1. Bayer Partnership with Broad Institute
  2. Immunotherapy Combination of Biomarkers
  3. Sharing Data from Clinical Trials
  • Seema Singh Bhan, Head, Public Policy, Foundation Medicine
  1. Technology to
  2. harness Big data
  3. Momentum via NCI, Cancer Moonshot
  4. Foundation Medicine: Collaboration: Pharma, Goventment, FDA, Academic Institution 0 Liquid Biopsy assays developed and go through the Regulatory system
  5. Patient-Doctor – List of Clinical Trials available for Patients

2:30 – 3:15 Breakout Sessions

  • 2:30 pm 3:15 pm
  • CRISPR and What’s Next

    Trends in Science
    2:30 pm 3:30 pm
Scott Gillis, CEO, Onsite Therapeutics, Inc.
  1. implantation of gene edited cells in Human in China
  2. Bio Ethics
  • Jim Burns, President & CEO, Casebia Therapeutics, ex-Sanofi-Genzym
  1. How to deliver tissue specific in vivo
  2. Hymophylia
  3. Immunodefficiency
  4. 30 emp – 60 emp year end
  5. Incubate ideas
  6. Joint venture CRISPR Therapeutics and Casebia
  7. guidelines from the National Academy


  • George M. Church, Harvard Prof. of Genetics – now speaks for Genesis
  1. In one year Clinical trial of porcine organ lab made – organ transplant
  2. build new tool set write not read
  • Mattew Stanton, VP, Head of Chemistry, Moderna Therapeutics, ex-Merck
    1. mRNA, 500 emp, Kendall Sq. immun-ooncology, nanoparticle delivery ZIKA Vaccine,
    2. electroporation – delivery
    4. original work on siRNA and mRNA – helps the state of today
  • Bill Lundberg, Stanford, MD – MIT, PhD, CSO of CRISPR Therateutics, ex-Genzyme
  1. liver delivery requires dirrrect delivery vs another organ take cells ex-vivo transfact and implant back
  2. UPenn – edited T-cells to human will be first in the US
  3. Somatic cell edition not germline, inheritence



3D Printing and BioEngineering



2:30 pm 3:30 pm

Afternoon Break

3:30 pm 3:45 pm

Patient Story

3:45 pm 3:50 pm

Biotech in the Era of Real World Evidence/Drug Value Panel

3:50 pm 4:30 pm
Leora Schiff, COnsulting COmpanyEvidence sought by Payers to define Value
  1. Industry has changed, R&D to commercialization
  2. Value and Evidence – why it matters in Biotech Industry
  • Joshua Cohen, Research Associate Prof. Tufts Center for the Study of Drug Development, Value assessment
  1. Value – what people care: Survival
  2. What makes sense
  • Gigi Hirsh, Executive Director, Center Biotech Innovations, MIT and Program Director, NEWDIGS (New Paradigms)
  1. Product life Cycles
  2. Value as defined availability dat on WOrldwide samples
  3. Regulatory – 70 years of data, now diverse data sources
  4. Standard for data not available
  5. Structured methodology on a Product Plan for the Product Life Cycle
  • C. David Nicholson, Chief R&D Officer, Allergan
  1. How to convince Regulator of Value
  2. Drugs goes to Formulary based on Value in need to be demonstrated
  3. In the UK, Drug Prices are set by a centralized organization for the Universal HealthCare system in the UK
  4. Me to drugs are dead, ONLY new drugs with Value survive
  5. Budget for drugs – in the US it is Total HealthCare cost vs UK with a universal HC system,
  • Bill Sibnold, Global Franchise Head, MS Oncology and Immunology, Sanofi Genzyme
  1. How to create a system to thrive,
  2. How access to a product is defined From R&D to commercialization
  3. Products are coming to market with data for standard of care comparison

Patient Story

4:30 pm 4:35 pm

Networking Reception

4:35 pm 6:00 pm

Read Full Post »

16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Reporter: Aviva Lev-Ari, PhD, RN


Summer Symposium 2017


A leader in Convergence, MIT’s Koch Institute for Integrative Cancer Research will, on June 16, present its 16th annual Summer Symposium: the Convergence of Science and Engineering in Cancer Research. Convergence—the merging of historically distinct disciplines such as engineering, physics, computer science, chemistry, mathematics, and the life sciences—has created extraordinary opportunities in cancer research and care. Leaders in this emerging field will discuss innovative new approaches and technologies to better detect, monitor, treat, and prevent cancer. The symposium will also feature a panel of experts to discuss the impact of Convergence on the future of medical care.


Tyler Jacks Tyler Jacks, PhD
Director, Koch Institute, MIT
David H. Koch Professor of Biology, MIT


Phillip A. Sharp  

Phillip A. Sharp, PhD
Institute Professor, MIT
Koch Institute, MIT



Eric Lander

30 Years of Convergence

Eric Lander, PhD
President and Founding Director, Broad Institute of Harvard and MIT
Professor of Biology, Department of Biology, MIT
Koch Institute, MIT
Professor of Systems Biology, Harvard Medical School



James Collins

Synthetic biology and next-generation diagnostics

James Collins, PhD
Termeer Professor of Medical Engineering and Science and Professor of Biological Engineering, MIT
Broad Institute of Harvard and MIT
Wyss Institute


Gad Getz

Cancer Genome and the Cloud

Gad Getz, PhD
Director, Cancer Genome Computational Analysis Group, Broad Institute of Harvard and MIT


Paula Hammond

Targeting Aggressive Cancers Nanolayers at a Time: A Platform Approach to Engineered Nanomedicine

Paula T. Hammond, PhD
David H. Koch Professor in Engineering, MIT
Head of the Department of Chemical Engineering, MIT
Koch Institute, MIT


Robert Langer

New chemical engineering approaches to convergence

Robert S. Langer, ScD
David H. Koch Institute Professor, MIT
Koch Institute, MIT


Daniel Larson

Understanding transcription and splicing heterogeneity in cancer progression

Daniel Larson, PhD
NIH Stadtman Investigator, Center for Cancer Research
Head, Systems Biology of Gene Expression, National Cancer Institute


Franziska Michor

Computational Models of Cancer

Franziska Michor, PhD
Professor of Computational Biology, Dana-Farber Cancer Institute
Harvard T.H. Chan School of Public Health


Chad A. Mirkin

Spherical Nucleic Acids as a Powerful New Platform for Cancer Therapy

Chad A. Mirkin, PhD
Director, International Institute for Nanotechnology
George B. Rathmann Professor of Chemistry, Department of Chemistry, Northwestern University


Aviv Regev

Dissecting the tumor ecosystem with single cell genomics

Aviv Regev, PhD
Core Institute Member, Chair of the Faculty, Broad Institute of Harvard and MIT
Co-director of the Cell Circuits Program, Broad Institute of Harvard and MIT
Koch Institute, MIT


Xiaowei Zhuang

Illuminating biology at the nanoscale and systems scale using single-molecule and super-resolution imaging

Xiaowei Zhuang, PhD
David B. Arnold Professor of Science, Harvard University
Howard Hughes Medical Institute Investigator



Cori Bargmann  

Cori Bargmann, PhD
President of Science, Chan Zuckerberg Initiative


Marc N. Casper  

Marc N. Casper, MBA
President and CEO, Thermo Fisher Scientific


Victor Dzau  

Victor Dzau, MD
President, National Academy of Medicine


Tyler Jacks  

Tyler Jacks, PhD
Director, Koch Institute, MIT
David H. Koch Professor of Biology, MIT


Nancy Simonian  

Nancy Simonian, MD
CEO, Syros Pharmaceuticals, Inc.


Elias Zerhouni  

Elias Zerhouni, MD
President for Global Research and Development, Sanofi
Former Director, NIH


Susan Hockfield

Moderated by:

Susan Hockfield, PhD
President Emerita, MIT
Professor of Neuroscience, MIT
Koch Institute, MIT


Read Full Post »

The 13th Annual Personalized Medicine Conference: “From Concept to the Clinic”, November 14 – 16, 2017, Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur, Boston

Reporter: Aviva Lev-Ari, PhD, RN


The 13th Annual Personalized Medicine Conference will blend an exploration of all the issues facing personalized medicine with practical insights from both clinical experts and patients on how to move evolving concepts into the clinic. Among other topics, the program will cover value frameworks and pharmaceutical pricing, the implications of gene therapy and gene editing, the Trump administration’s perspectives on personalized medicine, and the role of big data.

The dialogue at the conference shapes the community’s agenda and guides the Coalition’s work. Anyone with an interest in the field is welcome to participate.



From: <pmc@personalizedmedicinecoalition.org>

Date: Monday, March 13, 2017 at 10:19 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: The 13th Annual PM Conference: “From Concept to the Clinic”

Read Full Post »

2017 MassBio Annual Meeting  March 30, 2017 8:00 AM – March 31, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA

Reporter: Aviva Lev-Ari, PhD, RN

 Leaders in Pharmaceutical Business Intelligence will cover the event

Aviva Lev-Ari, PhD, RN

will be streaming content using Social Media from the Royal Sonesta Boston on 3/30 and 3/31 in



2017 MassBio Annual Meeting

March 30, 2017 8:00 AM March 31, 2017 4:00 PM
Royal Sonesta Boston40 Edwin Land BoulevardCambridge MA US 02142


UPDATED on 3/2/2017

Governor Charlie Baker to Address MassBio’s Annual Meeting

MassBio is thrilled to announce that Governor Charlie Baker will address attendees of MassBio’s 2017 Annual Meeting, which focuses on the most critical challenges facing the Massachusetts life sciences industry. 

Check out some recent news stories on Governor Baker:  

We’re #1: US News & World Report Ranks Massachusetts Best State

CBS Boston, 2/28/2017

Massachusetts Puts $39 Million Behind STEM Education

CivSource, 2/22/2017

Baker backs immigrant visas for Mass. firms

The Boston Globe, 2/4/2017

Plenary Sessions

Value: Biotech in the Era of Real-World Evidence
It is a time of great change in healthcare, as patients seek insight and engagement in the development of treatments, policymakers disagree on whether to regulate the industry more or less, and the market shifts from volume-based to value-based payment models. With scientific discovery advancing faster than innovations to our insurance and payment models, how do biopharma companies plan for bringing new treatments to market?

We will discuss the trends toward convergence in drugs, diagnostics, devices and digital health

Cancer Moonshot: Where Des it Go From Here?

Better Business Track

The Next Generation
What are the challenges facing young researchers and new entrepreneurs today? We’ will discuss workforce development, diversity, the funding environment and more.

Changes in the Valley of Death
There is much hand-wringing over the challenges of getting early-stage funding today. But there has always been a “valley of death” in biotech. How is today’s valley different than in years past? Is it really harder to raise money today? How is the diverse and fragmented funding environment making the process harder or easier?

Emerging Markets in the Global Landscape
How are emerging markets and today’s global landscape impacting biopharma strategy?

Trends in Science Track

We will discuss current research and trends in Parkinson’s, Alzheimer’s, and other CNS diseases

CRISPR and What’s Next
A look at where CRISPR technology is heading and the next generation of gene editing tools (CAS9, Cpf1, etc.)

Pain & Addiction
We all understand the devastation that prescription drug addiction is causing in our society. But we can’t eliminate addiction until we discover a non-addictive method for treating pain. What’s next for pain?

As the population ages and lives longer, there is significant opportunity in research and treating diseases of aging. We will discuss osteoarthritis, hearing loss, Alzheimer’s, dementia and other health conditions related to aging.

Convergence Track (New for 2017!)

Funding Issues at the Intersections
Despite the hype about cross-industry collaboration and convergence, it is hard to raise money for technologies at the intersections of these industries. Who is funding convergent ideas and how do you sell them?

Big Data Analytics Possibilities

Next Generation Diagnostics

FDA Policy




Read Full Post »

2017 Agenda – BioInformatics: Track 6: BioIT World Conference & Expo ’17, May 23-35, 2017, Seaport World Trade Center, Boston, MA

Reporter: Aviva Lev-Ari, PhD, RN







7:00 am Workshop Registration and Morning Coffee

8:0011:30 Recommended Morning Pre-Conference Workshops*

(W4) Data Visualization to Accelerate Biological Discovery

12:304:00 pm Recommended Afternoon Pre-Conference Workshops*

(W13) Proteogenomics: Integration of Genomics and Proteomics Data

* Separate registration required.

2:006:00 Main Conference Registration Open


Click here for detailed information

5:007:00 Welcome Reception in the Exhibit Hall with Poster Viewing


7:00 am Registration Open and Morning Coffee


Click here for detailed information

9:50 Coffee Break in the Exhibit Hall with Poster Viewing


10:50 Chairperson’s Remarks

Kevin Merlo, BioSafety Development Engineer, Dassault Systemes

11:00 Innovative Data Integration Applicable for Therapeutic Protein Development 2.0

Wolfgang Paul, Group Leader and Senior Scientist, Large Molecule Research, Roche

Therapeutic proteins are registered including sequence, structural and functional data and information. Millions of data points are captured during the development of Roche’s innovative therapeutic proteins in data warehouse used by DAMAS (data acquisition, management and analyses system). Fast access and visualization of relevant process and analytical data drive scientific discussion and decision making. Analyzing the stored big data is key towards process development of therapeutic proteins 2.0.

11:30 Informatics – A Silver Bullet for Pharmaceutical Sciences?

William Loging, Ph.D., Associate Professor of Genomics & Head, Production Bioinformatics, Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai

The Pharmaceutical Sciences field is in constant search for the next big innovative push that will increase the success rate of drug programs. The fields of computational chemistry, structural bioinformatics – just to name a few – have changed the way drug researchers look for and identify novel drug candidates. Utilizing more than 15 years of Pharmaceutical experience, and using real world examples of high provide drug projects, this talk will provide practical steps for the merger of informatics and the strategic approaches needed for drug discovery success.

12:00 pm Big Data-Driven Bioinformatics

Frank Lee, Ph.D., Healthcare Life Sciences Industry Leader, Software Defined Infrastructure, IBM Systems, IBM

IBM will discuss the IBM Reference Architecture for Genomics, its new features, and case studies: hybrid cloud with integrated workload and data management for high performance genomics analytics; container technologies for migrating and sharing application and data; and application portal and metadata engine for global access to and searching of distributed resources. A demo of a hybrid cloud-based bioinformatics solution will follow.

12:30 Session Break

12:40 Luncheon Presentation I to be Announced

1:10 Luncheon Presentation II to be Announced

1:40 Session Break


1:50 Chairperson’s Remarks

1:55 PANEL DISCUSSION: Linking and Finding Information Using the IUPAC InChI Standard for Chemical Structures

Steve Heller, Ph.D., Project Director, InChI Trust; Scientific Information Consultant (Moderator)

Evan Bolton, Ph.D., Lead Scientist, National Center for Biotechnology Information (NCBI), National Library of Medicine (NLM), and National Institutes of Health (NIH)

Keith T. Taylor, BSc, Ph.D., MRSC, Principal, Ladera Consultancy

Tyler Peryea, Informatics Scientist, National Center for Advancing Translational Sciences (NCATS)

Lawrence Callahan, Ph.D., Chemist, Substance Registration System, Office of Critical Path Programs, Food and Drug Administration (FDA)

This session will highlight on-going efforts to strengthen and expand the non-proprietary IUPAC International Chemical Identifier (InChI) standard for chemical structures and its hashed-form, the InChIKey. Information standards are critical to enable effective communication of scientific content. Funding to maintain InChI comes from most major publishers and database providers as well as governmental agencies (NIH, FDA and NIST). The InChI is an open-source, widely adopted standard found in most chemical information containing databases, including those from Chemical Abstracts, Reaxys, ChEMBL, OpenPHACTS, PubChem, DrugBank, PDB, Sigma-Aldrich, and many others, such as internal Pharma corporate databases. InChI is an addition to a database, not a replacement. With the implementation of the ISO identification of medicinal products (IDMP) and the related ISO 11238 standards, adding and having an InChI will allow for an easier, effective, and more complete search for information on a particular drug.

2:55 Sponsored Presentation (Opportunity Available)

3:10 Integrated Informatics for Biologics Discovery

Robert Brown, Ph.D., Vice President, Product Marketing, Dotmatics

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing


4:00 Building Disease Networks Using Text Mining and Machine Learning Techniques

Kamal Rawal, Ph.D., Assistant Professor, Biotech and Bioinformatics, Jaypee Institute of Information Technology

Obesity is a global epidemic affecting over 1.5 billion people and is one of the risk factors for several diseases such as type 2 diabetes mellitus and hypertension. We have constructed a comprehensive map of the molecules reported to be implicated in obesity. Using text mining & deep curation strategies combined with omics data, we have explained the therapeutics and side effects of several drugs (i.e., orlistat) at network level.

4:20 Big Data and Systems Biology: From Genome to Phenome (and Everything in Between)

Dan Jacobson, Ph.D., Computational Biologist, Oak Ridge National Laboratory

4:40 Novel Feature Selection Strategies for Enhanced Predictive Modeling and Deep Learning in the Biosciences

Tom Chittenden, Ph.D., D.Phil., Lecturer and Senior Biostatistics and Mathematical Biology Consultant, Harvard Medical School

We have built a robust AI approach that precisely assesses pathogenicity for all genomic missense variants. Coupled with our advanced deepCODE mathematical statistics feature selection strategy for constructing deep learning models, we are able to quantitatively integrate a priori pathway-based biological knowledge with multiple types of high-throughput omics data.

5:00 Network Analysis for Drug Discovery: Benchmarking Results and Best Practices Reported by CBDD Consortium

Marina Bessarabova, Ph.D., Senior Director, Discovery and Translational Science, Life Sciences Professional Services, Clarivate Analytics (Formerly the IP & Science Business of Thomson Reuters)

A large number of advanced approaches to network analysis of -omics data were developed by academia groups in the past 15 years. Adoption of these approaches in drug development requires thorough review of the published approaches, implementation of methods identified as potentially applicable to drug development and benchmarking of the methods with an aim to establish best practices for application of the methods to diseases and mechanism of action understanding, target identification, drug repositioning, patient stratification, biomarker discovery, and drug combination effect prediction. CBDD (Computational Biology Methods for Drug Discovery) is a precompetitive consortium between Novartis, Pfizer, Sanofi, Janssen, Regeneron, UCB, Roche, Takeda, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Merck and Clarivate Analytics (formally Thomson Reuters) focused on adoption of network analysis approaches in drug development: literature review, method implementation and benchmarking. Benchmarking results and best practices for application of network analysis in drug development established by members of the program will be shared during the presentation.

5:30 15th Anniversary Celebration in the Exhibit Hall with Poster Viewing and Best of Show Awards


7:00 am Registration Open and Morning Coffee


8:05 Benjamin Franklin Awards and Laureate Presentation

8:35 Best Practices Awards Program

8:50 Plenary Keynote

Click here for detailed information

9:45 Coffee Break in the Exhibit Hall and Poster Competition Winners Announced


10:30 Chairperson’s Remarks

Bino John, Ph.D., Computational Biology Group Leader, Dow AgroSciences LLC

10:40 How Biotech and Big Data Are Changing Agro Industry

Bino John, Ph.D., Computational Biology Group Leader, Dow AgroSciences LLC

More than 70% of the increase in food production in the next 50 years is expected to come from technological advances. Indeed, recent advances in genomics and phenomics are beginning to transform the Agro-industry, whereby creating new opportunities for informatics disciplines. While informatics needs in managing, analyzing, and visualizing big data share commonalties between Agro and the biomedical communities, Agro companies face unprecedented challenges in big biological data, generally larger than their peers in the biomedical community.

11:00 Offering Outcomes: How Digital Farming Data Is Enabling New Business Models

Tobias Menne, Global Head of Digital Farming, Bayer

11:20 Building the Next-Generation R&D IT Infrastructure for Small Molecule Discovery

Paimun Amini, Chemistry IT Lead, R&D IT, Monsanto Company

Barrett Foat, Ph.D., Data Science Team Lead, Agricultural Productivity Innovations, Monsanto

The Pharma boom in the 90s & 2000s led to the emergence of a rich ecosystem of software companies focused on delivering the IT needs for small molecule discovery. Today, cloud data storage, IoT, and the growth of predictive analytics present new opportunities for the evolution of the R&D pipeline. New technologies allow for integrated software and hardware solutions that optimize productivity while removing the risk of technical debt.

11:40 Sponsored Presentation (Opportunity Available)

12:10 pm Session Break

12:20 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Dessert Refreshment Break in the Exhibit Hall with Poster Viewing


1:55 Chairperson’s Remarks

Michael N. Liebman, Ph.D., Managing Director, IPQ Analytics, LLC and Strategic Medicine, Inc.

2:00 Distinguishing between Precision Medicine and Accurate Medicine: Application to Heart Failure Patients and Clinical Practice

Michael N. Liebman, Ph.D., IPQ Analytics, LLC and Strategic Medicine, Inc.

Increasingly, patient stratification based on genomic analysis is being considered in disease management. Critically, the need to understand real world medical practice and real world patient complexities extends far beyond the genome of the patient. We have shown examples of this complexity in heart disease and how this impacts development of clinical guidelines, trial design, and development of new patient management approaches.

2:30 CARPEDIEM – Comorbidity and Risk Profiles Evaluation in Diabetes and Heart Morbidities

Sabrina Molinaro, Psy.D., Ph.D., Head, Department of Epidemiology and Health Services, Institute of Clinical Physiology, National Research Council of Italy

Our project uniquely develops a patient record that includes clinical and individual factors (EHR-driven phenotyping) that will be validated through the comparison of existing standards for building new risk algorithms. An understanding of the current limitations and biases of risk profiling in heart disease and diabetes and how an extended, integrated database and automatic rule-based classification system can be used to improve patient management.

3:00 PANEL DISCUSSION: Precision Medicine vs. Accurate Medicine: The Need to Understand Real World Medicine and Real World Patients

Michael N. Liebman, Ph.D., IPQ Analytics, LLC and Strategic Medicine, Inc. (Moderator)

Charles Barr, M.D., MPH, Group Medical Director and Head, Evidence Science and Innovation, Genentech

Hal Wolf, Director, National Leader of Information and Digital Health Strategy, The Chartis Group

4:00 Conference Adjourns



Read Full Post »

The 35th Annual J.P. Morgan Healthcare Conference, January 9, 2017 to January 13, 2017, Westin St. Francis Hotel, San Francisco

Reporter: Aviva Lev-Ari, PhD, RN


BioPharm Insight Exclusive Event


Panel Discussion 5:30 – 6:30 PM 
Immuno-Oncology: Filtering the hype for the next wave of targets

Panel discussion as key opinion leaders (KOLs) and industry experts take on the tough questions in the field. Topics to be discussed include next-generation I/O therapeutics, pricing and reimbursement expectations, and more.

Axel Hoos, MD, PhD, SVP Oncology R&D, GSK
Ira Mellman, PhD, VP Cancer Immunology, Genentech
Lindee Goh, Partner, Tapestry Networks
Omid Hamid, MD, Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic
Ramy Ibrahim, MD, VP and Head of R&D, Parker Institute for Cancer Immunotherapy
Moderated by Querida Anderson, Editor in Chief at BioPharm Insight

*This panel is brought to you by BioPharm Insight and The Immuno-Oncology 360° team at The Conference Forum

Networking Reception 6:30 – 8:30 PM

You’re invited to join us for a networking reception following the panel discussion. We know how busy this week is, so feel free to pop-in after the panel for cocktails and light fare. Mix and mingle with the BioPharm Insight team, industry experts and fellow peers.

JANUARY 9, 2017

Chandran Art Gallery

459 Geary St

San Francisco, CA




Read Full Post »

Older Posts »